At a Glance
- Companies: MediLink Therapeutics; Roche
- Locations: Suzhou, China (MediLink); Basel, Switzerland (Roche)
- Deal value: $570m upfront/near‑term; additional milestones; tiered royalties ex‑China
- Focus area: YL201, B7H3‑targeting ADC for solid tumours including SCLC and NPC
- Next steps: Roche to develop/commercialise globally ex‑China; two China phase 3 trials ongoing
What happened?
MediLink Therapeutics has signed an expanded collaboration and exclusive licensing agreement with Roche for YL201, a B7H3‑targeting antibody‑drug conjugate (ADC) for solid tumours. Roche gains exclusive rights to develop, manufacture and commercialise YL201 worldwide excluding mainland China, Hong Kong SAR and Macau SAR, with MediLink receiving $570 million in upfront and near‑term milestone payments plus further biobucks and tiered royalties.
Why does it matter?
YL201 leverages MediLink’s proprietary TMALIN platform for tumour microenvironment‑activatable linker‑payload release, showing promising ORR and survival in second‑line small cell lung cancer (SCLC) and advancing to phase 3 in SCLC and nasopharyngeal carcinoma (NPC) in China. The FDA breakthrough designation for SCLC (June 2025) and orphan status for SCLC, NPC and oesophageal squamous cell carcinoma underscore its potential in underserved solid tumours.
Who’s behind it?
MediLink is a China‑based clinical‑stage biotech with 13 TMALIN ADCs, including prior Roche partner YL211 (c‑Met). Roche is a global oncology leader with ADC expertise (e.g. Polivy, Columvi) expanding into next‑gen payloads and targets.
How was it achieved?
Building on the 2024 YL211 deal, Roche’s global infrastructure accelerates YL201’s multinational trials while MediLink retains Greater China rights, combining complementary strengths for faster approvals.
What’s next?
Roche will prioritise global development for advanced solid tumours, while MediLink advances China phase 3 trials. Success could validate TMALIN for broader oncology applications.
What are people saying?
MediLink CEO Dr Tongtong Xue praised Roche’s “unparalleled expertise in global clinical development”. CSO Dr Jiaqiang Cai called it a “transformative step” for YL201’s worldwide reach. Roche’s Boris Zaïtra highlighted commitment to “cutting‑edge innovation” in oncology priorities like lung cancer.